Radiation procedure to prevent closing of arteries after angioplasty and stenting approved by FDA for expanded use with patients

August 10, 2000

Clinical trial being conducted at Rush-Presbyterian-St. Luke's Medical Center

A clinical trial on a procedure that delivers radiation to arteries to prevent them from re-closing after patients are treated with angioplasty and stenting has been so successful that the Food and Drug Administration (FDA) announced that the trial can be expanded. Now, cardiologists at Rush-Presbyterian-St. Luke's Medical Center, who were among the original investigators in the clinical trial, can treat all patients who met the enrollment criteria for the clinical trial with the low-dose radiation. In the clinical trial begun two years ago, patients enrolled were given either radiation or standard angioplasty to treat arteries that reclosed (restenosis) after prior angioplasty or stenting. Stents are spring-like devices that keep blood vessels open that might otherwise close after angioplasty. With the FDA approved expansion, many patients with restenosis can now receive the radiation. Restenosis is the primary limitation of current therapies used to open blocked arteries.

Studies show that 30-50 percent of people who undergo angioplasty to open blocked arteries may experience restenosis within six months of the procedure. "The initial phase of the research trial showed a dramatic 66 percent reduction in in-stent restenonsis, documented by angiography," said Dr. Gary Schaer, co-principal investigator and director of the cardiac catheterization laboratory at Rush. Dr. Schaer is co-principal investigator along with Dr. Jeffrey Snell.

"This re-narrowing happens because cells in the artery wall divide and proliferate as a healing response to the injury caused by the angioplasty balloon or stent placement. Low-dose local radiation therapy actually inhibits the cells' ability to respond in this way, thereby substantially reducing the re-narrowing response," Schaer said.

During angioplasty, a cardiologist threads a balloon catheter through the femoral artery - accessed in the thigh - to the coronary artery in the heart. Once the catheter is positioned at the site of the blockage, the balloon is expanded, pressing plaque against the artery wall to open the artery and restore blood flow.

Immediately after the balloon procedure, cardiologists use the Beta-Cath System to advance tiny metal beads within the catheter to the section of artery previously opened by the balloon catheter. The metal beads emit beta radiation to the inside of the artery for fewer than five minutes and are then withdrawn from the body. The amount of radiation exposure is considerably less than what a patient would receive during a chest x-ray.

The Beta Cath device could reduce the need for bypass surgery or other cardiac treatment procedures for people with coronary artery disease, according to cardiologists at Rush. Rush is one of 50 sites nationwide participating in a clinical trial testing the safety and efficacy of the device under direction of the FDA.

"Rush is in a good position to offer this promising new treatment because we have performed well over 100 Beta Cath procedures," Snell said. More than 13 million people in the United States have been diagnosed with coronary artery disease, the leading cause of death in this country. This year alone, an estimated 1.8 million patients will undergo procedures such as coronary bypass surgery and balloon angioplasty to reopen their arteries.
Rush-Presbyterian-St. Luke's Medical Center includes the 809-bed Presbyterian-St. Luke's Hospital; 154-bed Johnston R. Bowman Health Center for the Elderly; Rush University (Rush Medical College, College of Nursing, College of Health Sciences and Graduate College); and seven Rush Institutes providing diagnosis, treatment and research into leading health problems. The medical center is the tertiary hub of the Rush System for Health, a comprehensive healthcare system capable of serving about two million people through its outpatient facilities and five member hospitals.

Rush University Medical Center

Related Angioplasty Articles from Brightsurf:

Ticagrelor was not superior to clopidogrel to reduce heart attack risk during angioplasty
A new study found the rate of heart attack and severe complications before, during or soon after elective surgery to open a blocked artery was similar between patients treated with clopidogrel and those who received the more potent antiplatelet medication ticagrelor.

Study finds significant variability in doctors' angioplasty death rates
Some doctors have higher or lower than expected death rates from coronary angioplasty procedures, also known as percutaneous coronary intervention (PCI); however, doctors should not be judged solely on the rate of patients who die from the procedure.

Beta-blockers following angioplasty show little benefit for some older patients
Following coronary angioplasty, beta-blockers did not significantly improve mortality rates or reduce the number of future cardiovascular incidents for older patients with stable angina but no history of heart attack or heart failure, according to a study published today in the JACC: Cardiovascular Interventions.

Sleep disorders may predict heart events after angioplasty
People who have had procedures to open blocked heart arteries after acute coronary syndrome (ACS) may have a higher risk of death, heart failure, heart attack and stroke if they have sleep disorders, such as sleep apnea, compared to those who don't.

Reasons for hospital-level variations in bleeding post-angioplasty are unclear
The use of bleeding avoidance strategies has only a modest effect on the variation in bleeding rates post-angioplasty among hospitals performing this procedure, leaving about 70 percent of the causes for this variation unexplained, according to a study published today in JACC: Cardiovascular Interventions.

US prediction models for kidney injury following angioplasty hold up in Japan
Models developed by the American College of Cardiology NCDR CathPCI Registry to predict the likelihood of angioplasty patients developing acute kidney injury and acute kidney injury requiring dialysis have proven to be effective among patients in Japan.

IV beta blockers before angioplasty are safe, but offer no clinical benefit
Giving intravenous beta blockers before performing a coronary angioplasty in patients who had experienced the deadliest form of heart attack -- ST-segment elevation myocardial infarction (STEMI) -- was safe but did not reduce heart attack severity or improve blood flow from the heart's main pumping chamber, according to research presented at the American College of Cardiology's 65th Annual Scientific Session.

Life-threatening bowel ischemia can often be treated by balloon angioplasty
Acute mesenteric ischemia (AMI) can be successfully treated with endovascular therapy such as balloon angioplasty, according to research from the University of Eastern Finland.

Radial access used less than femoral approach for emergency angioplasty
Although using the radial artery as the access point for angioplasty has been linked to reduced bleeding compared to use of the femoral artery, only a small number of high-risk heart attack patients who undergo rescue angioplasty -- emergency procedures following failed therapy with clot-busting drugs -- are treated by radial access, according to a study published today in the Journal of the American College of Cardiology: Cardiovascular Interventions.

Use of rarely appropriate angioplasty procedures declined sharply
The number of angioplasty procedures classified as rarely appropriate declined sharply between 2010 and 2014, as did the number of those performed on patients with non-acute conditions, according to a study published today in the Journal of the American Medical Association and simultaneously presented at a meeting of the American Heart Association in Orlando.

Read More: Angioplasty News and Angioplasty Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.